AstraZeneca plc (NYSE:AZN) has been collaboratively developing a coronavirus vaccine with Oxford University but the two were recently forced to halt clinical trials after a patient in the UK suffered a major reaction.
Extreme adverse effects are the biggest concern for any pharmaceutical company in the process of clinical testing their pipeline drugs because it might invalidate their research. AstraZeneca's pipeline vaccine encountered a potentially damaging roadblock last week after one of the patients enrolled in a clinical trial suffered a spinal injury related to the treatment. The company had to halt the clinical trial to prevent further risk on the trial subjects and also to pave way for investigations to determine what happened.
Is Astrazeneca’s vaccine in danger of being scrapped?
This was the question that many, especially the company’s investors were wondering. UK regulators quickly swooped in to conduct independent investigations aimed at providing a clear view of whether the pipeline coronavirus vaccine was too risky for human use. The investigations were conducted by the Medicines and Healthcare products Regulatory Agency (MHRA).
The MHRA concluded that the UK patient suffered the spinal injury due to a rare spinal inflammatory disease known as transverse myelitis. The decision was enough for UK regulators to allow AstraZeneca and Oxford to resume the clinical study in the country. There have been reports that the U.S Food and Drug Administration might also follow in the steps of the British regulators, to allow the biopharma to continue the clinical study.
The decision by UK regulators to allow AstraZeneca to continue with the clinical study means that the company will likely still roll out the vaccine to the masses if it proves to be reliable enough. AstraZeneca is one of the companies that joined the race to find a cure or working vaccine to combat the coronavirus pandemic. So far no company has rolled out a working vaccine but the results of some companies so far indicate that they are getting closer to a rollout.